Your browser doesn't support javascript.
loading
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma.
Yen, Ivana; Shanahan, Frances; Lee, Jeeyun; Hong, Yong Sang; Shin, Sang Joon; Moore, Amanda R; Sudhamsu, Jawahar; Chang, Matthew T; Bae, Inhwan; Dela Cruz, Darlene; Hunsaker, Thomas; Klijn, Christiaan; Liau, Nicholas P D; Lin, Eva; Martin, Scott E; Modrusan, Zora; Piskol, Robert; Segal, Ehud; Venkatanarayan, Avinashnarayan; Ye, Xin; Yin, Jianping; Zhang, Liangxuan; Kim, Jin-Soo; Lim, Hyeong-Seok; Kim, Kyu-Pyo; Kim, Yu Jung; Han, Hye Sook; Lee, Soo Jung; Kim, Seung Tae; Jung, Minkyu; Hong, Yoon-Hee; Noh, Young Su; Choi, Munjeong; Han, Oakpil; Nowicka, Malgorzata; Srinivasan, Shrividhya; Yan, Yibing; Kim, Tae Won; Malek, Shiva.
Afiliación
  • Yen I; Department of Discovery Oncology, Genentech Inc., South San Francisco, CA, USA.
  • Shanahan F; Department of Discovery Oncology, Genentech Inc., South San Francisco, CA, USA.
  • Lee J; Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Hong YS; Department of Intelligence Precision Healthcare Convergence, Samsung Medical Center, Sungkyunkwan University School of Medicine, Suwon, South Korea.
  • Shin SJ; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Moore AR; Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.
  • Sudhamsu J; Department of Discovery Oncology, Genentech Inc., South San Francisco, CA, USA.
  • Chang MT; Department of Discovery Oncology, Genentech Inc., South San Francisco, CA, USA.
  • Bae I; Department of Structural Biology, Genentech Inc., South San Francisco, CA, USA.
  • Dela Cruz D; Department of Bioinformatics, Genentech Inc., South San Francisco, CA, USA.
  • Hunsaker T; Department of New Chemical Entity Discovery, Hanmi Research Center, Hanmi Pharmaceutical Co., Ltd., Seoul, South Korea.
  • Klijn C; Department of Translational Oncology, Genentech Inc., South San Francisco, CA, USA.
  • Liau NPD; Department of Translational Oncology, Genentech Inc., South San Francisco, CA, USA.
  • Lin E; Department of Bioinformatics, Genentech Inc., South San Francisco, CA, USA.
  • Martin SE; Department of Structural Biology, Genentech Inc., South San Francisco, CA, USA.
  • Modrusan Z; Department of Discovery Oncology, Genentech Inc., South San Francisco, CA, USA.
  • Piskol R; Department of Discovery Oncology, Genentech Inc., South San Francisco, CA, USA.
  • Segal E; Department of Microchemistry, Proteomics and Lipidomics, Genentech Inc., South San Francisco, CA, USA.
  • Venkatanarayan A; Department of Bioinformatics, Genentech Inc., South San Francisco, CA, USA.
  • Ye X; Department of Translational Oncology, Genentech Inc., South San Francisco, CA, USA.
  • Yin J; Department of Discovery Oncology, Genentech Inc., South San Francisco, CA, USA.
  • Zhang L; Department of Discovery Oncology, Genentech Inc., South San Francisco, CA, USA.
  • Kim JS; Department of Structural Biology, Genentech Inc., South San Francisco, CA, USA.
  • Lim HS; Department of Oncology Biomarker Development, Genentech Inc., South San Francisco, CA, USA.
  • Kim KP; Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, South Korea.
  • Kim YJ; Department of Clinical Pharmacology and Therapeutics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Han HS; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Lee SJ; Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea.
  • Kim ST; Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, South Korea.
  • Jung M; Department of Oncology/Hematology, Kyungpook National University Chilgok Hospital, Kyungpook National University, Daegu, South Korea.
  • Hong YH; Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Noh YS; Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.
  • Choi M; Department of Clinical Research and Development, Hanmi Pharmaceutical Co., Ltd., Seoul, South Korea.
  • Han O; Department of Clinical Research and Development, Hanmi Pharmaceutical Co., Ltd., Seoul, South Korea.
  • Nowicka M; Department of Clinical Research and Development, Hanmi Pharmaceutical Co., Ltd., Seoul, South Korea.
  • Srinivasan S; Department of Clinical Research and Development, Hanmi Pharmaceutical Co., Ltd., Seoul, South Korea.
  • Yan Y; Department of Oncology Biomarker Development, Genentech Inc., South San Francisco, CA, USA.
  • Kim TW; Department of Oncology Biomarker Development, Genentech Inc., South San Francisco, CA, USA.
  • Malek S; Department of Oncology Biomarker Development, Genentech Inc., South San Francisco, CA, USA.
Nature ; 594(7863): 418-423, 2021 06.
Article en En | MEDLINE | ID: mdl-33953400
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Resistencia a Antineoplásicos / Quinasas raf / Proteínas Proto-Oncogénicas A-raf / Melanoma / Mutación Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Nature Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Resistencia a Antineoplásicos / Quinasas raf / Proteínas Proto-Oncogénicas A-raf / Melanoma / Mutación Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Nature Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos